Why Transational?

Translational science facilitates the translation of scientific discoveries into practical solutions that improve healthcare outcomes, accelerate innovation, address unmet medical needs, inform evidence-based practice, promote public health, and maximize the impact of research investments. By bridging the gap between bench science and bedside care, translational research ultimately helps to advance human health and well-being. 

The drug discovery process involves collaboration and coordination among a diverse range of actors, each contributing their expertise and resources to advance the development of new treatments and therapies for patients. 

Researchers and Scientists conduct basic and applied preclinical research to understand disease mechanisms, identify potential drug targets, and develop new compounds or therapies. Clinical Investigators conduct clinical trials to evaluate the safety and efficacy of new drugs in human subjects. Pharmaceutical and Biotechnology Company Investigators develop new drugs, conduct preclinical and clinical trials, and bring approved medications to market. 

The Cannabinoid Translational Science event will create a strict network (and an active interplay) between the needs/drawbacks/aims of three main actors of the drug discovery process who too often, despite being rings of the same chains, have a few occasions for confronting and brainstorming: 

• The medicinal/computational chemists (who design and synthesize the molecules);
• The biochemicals/pharmacologists (who validate in vitro and in vivo the synthesized molecules);
• The clinicians (who prescribe the molecules as drugs).